TransMedics (TMDX) Short term Debt (2025 - 2026)

TransMedics (TMDX) posted Short term Debt of $20.0 million for Q2 2026, up 33.33% on a QoQ basis from $15.0 million in Q1 2026.

Analysis

TransMedics (TMDX) Short term Debt (2025 - 2026) Analysis & Trends

TransMedics has reported Short term Debt for 2 years, with the latest figure at $20.0 million in Q2 2026.

On a quarterly basis, Short term Debt changed N/A year-over-year to $20.0 million in Q2 2026; TTM through Jun 2026 was $20.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.0 million, changed N/A from the prior year.
Short term Debt was $20.0 million for Q2 2026 at TransMedics, up from $15.0 million in the prior quarter.
The five-year high for Short term Debt was $20.0 million in Q2 2026, with the low at $5.0 million in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	183.04 Bn	177.44 Bn	7.27 Bn
2	Intuitive Surgical	125.02 Bn	119.81 Bn	1.96 Bn
3	Medtronic	117.84 Bn	109.02 Bn	6.34 Bn
4	Stryker	105.50 Bn	102.02 Bn	4.50 Bn
5	Boston Scientific	66.27 Bn	65.73 Bn	3.85 Bn
6	Edwards Lifesciences	49.60 Bn	45.35 Bn	1.35 Bn
7	Alcon	33.70 Bn	32.24 Bn	1.68 Bn
8	Dexcom	32.06 Bn	30.11 Bn	830.00 Mn
9	Steris	21.02 Bn	20.54 Bn	684.20 Mn
10	TransMedics	2.98 Bn	2.51 Bn	113.20 Mn

Historic Data

Download Data